Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOAT1 | P35610 | 6/20 | 0.63 |
| ▸ | ACAT1 | P24752 | 1/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CASP3 | P42574 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.36 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.36 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3378259 | 1.00 | SOAT1 (0.63) | SOAT1ACAT1KDM4ESMN1; SMN2HPGD | |
| SCHEMBL29972770 | 1.00 | SOAT1 (0.63) | SOAT1ACAT1KDM4ESMN1; SMN2HPGD | |
| SCHEMBL9597124 | 0.87 | SOAT1 (0.48) | SOAT1ACAT1 | |
| SCHEMBL9525341 | 0.86 | SOAT1 (0.47) | SOAT1ACAT1 | |
| SCHEMBL9201449 | 0.77 | SOAT1 (1.00) | SOAT1ACAT1 | |
| SCHEMBL3379092 | 0.77 | SOAT1 (1.00) | SOAT1ACAT1 | |
| Hydrochloric Acid SCHEMBL9212683 | 0.76 | SOAT1 (0.98) | SOAT1ACAT1 | |
| SCHEMBL9213110 | 0.76 | SOAT1 (0.98) | SOAT1ACAT1 | |
| SCHEMBL9202439 | 0.76 | SOAT1 (0.63) | SOAT1ACAT1KDM4ESMN1; SMN2HPGD | |
| SCHEMBL7640471 | 0.75 | KDM4E (0.36) | SOAT1ACAT1KDM4ESMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150087649-A1 | TREATING DISORDERS ASSOCIATED WITH ABERRANT ADRENOCORTICAL CELL BEHAVIOR | MILLENDO THERAPEUTICS, INC. | 2015-03-26 | — | — | US | disclosed |
| EP-0523941-A1 | Imidazoles as ACAT inhibitor | RHONE-POULENC RORER LIMITED (GB) | 1993-01-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150087649-A1 | TREATING DISORDERS ASSOCIATED WITH ABERRANT ADRENOCORTICAL CELL BEHAVIOR | ACAT1, CYP11A1, CYP11B1 | SOAT1 39/4885ACAT1 1/4885KDM4E 4072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.